Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months.78% of subjects maintained a ...
MURFREESBORO, TN / ACCESS Newswire / February 7, 2025 / National Health Investors, Inc. (NYSE:NHI) announced today that after more than 34 years of leadership and guidance on the NHI Board of ...
Sanofi announced its intention to execute a share buyback program in 2025 of €5 billion, preferably through block trades and in the open market with the purpose of cancellation. A first tranche of ...
The critical care patient monitoring product market has witnessed significant growth over the past few years. This surge can be attributed to advancements in healthcare technology, the increasing ...
Dermaliq Therapeutics, Inc. (Dermaliq) today announces that Ralf Paus, M.D., D.Sc., F.R.S.B. has joined the company’s Scientific and Medical Advisory Board.